FPHAX — Select Pharmaceuticals Portfolio
Data updated: 2026-07-24
FPHAX — Select Pharmaceuticals Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Global (incl. US) Health Care Equity · $1.50B AUM · 0.67% expense ratio · 44.6% 1-yr return. From SEC regulatory filings.
FPHAX Fund Overview
FPHAX — Select Pharmaceuticals Portfolio is a US mutual fund managed by Fidelity Select Portfolios, categorised as Global (incl. US) Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Select Portfolios
- Category: Global (incl. US) Health Care Equity
- Assets under management: $1.50B
- 1-year return: 44.6%
- Ticker: FPHAX
- SEC CIK: 0000320351
- SEC series ID: S000007481
- Share class ID: C000020455
FPHAX Holdings
Top 10 holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| ELI LILLY and CO | 28.78% |
| Gsk PLC | 8.17% |
| Viatris, Inc. | 5.45% |
| Ucb SA | 5.09% |
| MERCK and CO INC | 4.74% |
| Roche Holding AG | 4.54% |
| Legend Biotech Corp. | 4.53% |
| Astrazeneca PLC | 4.22% |
| Elanco Animal Health, Inc. | 4.15% |
| Jazz Pharmaceuticals PLC | 4.09% |
FPHAX Portfolio Allocation
Asset-class allocation of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.3% |
| Cash & Equivalents | 2.6% |
| Fixed Income | 0.2% |
FPHAX Performance
Total returns for FPHAX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 9.1% |
| 1 year | 44.6% |
| 3 years (annualised) | 18.5% |
| 5 years (annualised) | 13.2% |
FPHAX Risk Information
Risk metrics for FPHAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.0%
FPHAX Costs and Fees
FPHAX costs about $67 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.67%
- Gross expense ratio: 0.67%
- Portfolio turnover: 77%
- Brokerage commissions: 5.24 bps of average net assets (SEC N-CEN)
FPHAX Cashflows
Over the 12 months to 2026-02, Select Pharmaceuticals Portfolio had net outflows of $18.88M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | $8.43M |
| 2026-01 | $48.18M |
| 2025-12 | $66.93M |
| 2025-11 | $18.01M |
| 2025-10 | −$19.24M |
| 2025-09 | −$22.09M |
FPHAX Debt Constituents
Largest debt holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Evozyne, Inc. | 0.15% |
FPHAX Prospectus and SEC Filings
Official Select Pharmaceuticals Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Global (incl. US) Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.